GeneOne Life Science Inc (011000) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneOne Life Science Inc (011000) has a cash flow conversion efficiency ratio of -0.043x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.77 Billion ≈ $-1.20 Million USD) by net assets (₩40.90 Billion ≈ $27.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GeneOne Life Science Inc (011000) balance sheet quality index to measure how much of total assets are equity-financed.
GeneOne Life Science Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how GeneOne Life Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of GeneOne Life Science Inc to evaluate the quality of earnings relative to operating cash generation.
GeneOne Life Science Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneOne Life Science Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chesapeake Gold Corp.
V:CKG
|
-0.008x |
|
Humasis Co. Ltd
KQ:205470
|
0.036x |
|
Venu Holding Corporation
NYSE MKT:VENU
|
0.065x |
|
Perfect Corp.
NYSE:PERF
|
0.027x |
|
Jinzhou Port Co Ltd A
SHG:600190
|
-22.872x |
|
Srivichaivejvivat Public Company Limited
BK:VIH
|
0.041x |
|
Dollar Industries Limited
NSE:DOLLAR
|
0.049x |
|
AVerMedia Technologies Inc
TW:2417
|
0.036x |
Annual Cash Flow Conversion Efficiency for GeneOne Life Science Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of GeneOne Life Science Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see GeneOne Life Science Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩40.90 Billion ≈ $27.72 Million |
₩-16.54 Billion ≈ $-11.21 Million |
-0.404x | -115.61% |
| 2024-12-31 | ₩85.61 Billion ≈ $58.01 Million |
₩-16.06 Billion ≈ $-10.88 Million |
-0.188x | +3.82% |
| 2023-12-31 | ₩111.49 Billion ≈ $75.55 Million |
₩-21.74 Billion ≈ $-14.74 Million |
-0.195x | -46.78% |
| 2022-12-31 | ₩181.47 Billion ≈ $122.98 Million |
₩-24.11 Billion ≈ $-16.34 Million |
-0.133x | -462.98% |
| 2021-12-31 | ₩205.45 Billion ≈ $139.23 Million |
₩-4.85 Billion ≈ $-3.29 Million |
-0.024x | +85.39% |
| 2020-12-31 | ₩98.51 Billion ≈ $66.76 Million |
₩-15.92 Billion ≈ $-10.79 Million |
-0.162x | -206.09% |
| 2019-12-31 | ₩24.06 Billion ≈ $16.31 Million |
₩-1.27 Billion ≈ $-860.67K |
-0.053x | +78.64% |
| 2018-12-31 | ₩29.41 Billion ≈ $19.93 Million |
₩-7.27 Billion ≈ $-4.93 Million |
-0.247x | -123.54% |
| 2017-12-31 | ₩36.54 Billion ≈ $24.76 Million |
₩-4.04 Billion ≈ $-2.74 Million |
-0.111x | +68.00% |
| 2016-12-31 | ₩35.85 Billion ≈ $24.30 Million |
₩-12.39 Billion ≈ $-8.40 Million |
-0.346x | -1850.57% |
| 2015-12-31 | ₩39.44 Billion ≈ $26.73 Million |
₩778.50 Million ≈ $527.58K |
0.020x | +116.49% |
| 2014-12-31 | ₩34.73 Billion ≈ $23.54 Million |
₩-4.16 Billion ≈ $-2.82 Million |
-0.120x | -20.95% |
| 2013-12-31 | ₩23.71 Billion ≈ $16.07 Million |
₩-2.35 Billion ≈ $-1.59 Million |
-0.099x | -- |
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more